SecurityCHN / China Fund, Inc. (169373107)
Institutional Owners42
Institutional Shares14,209,585
Institutional Value$ 236,945,000 USD

Institutional Stock Ownership and Shareholders()

CHN / China Fund, Inc. Institutional Ownership

China Fund, Inc. (NYSE:CHN) has 42 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 14,209,585 shares. Largest shareholders include City Of London Investment Management Co Ltd, City Of London Investment Group Plc, Lazard Asset Management Llc, Wells Fargo & Company/mn, Bulldog Investors, LLC, Aberdeen Asset Management Plc/uk, Standard Life Aberdeen Plc, 1607 Capital Partners, LLC, Karpus Management, Inc., and Deschutes Portfolio Strategy, LLC.
China Fund, Inc. (NYSE:CHN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/chn"><img src="https://images.fintel.io/us-chn-so.png" alt="CHN / China Fund, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR Karpus Management, Inc. 267,202 389,198 45.66 5,785 8,617 48.95
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 16,741 14,881 -11.11 362 329 -9.12
2018-05-01 13F-HR BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC 598 598 0.00 12 13 8.33
2018-05-16 13F-HR Private Capital Group, Llc 29 1
2018-05-11 13F-HR Stevens First Principles Investment Advisors 3,840 0 -100.00 83 0 -100.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 2,771 1,975 -28.73 60 44 -26.67
2018-07-17 13F-HR Edge Wealth Management LLC 580 580 0.00 13 12 -7.69
2018-05-14 13F-HR Commonwealth Equity Services, Llc. 22,461 22,693 1.03 486 502 3.29
2018-05-15 13F-HR Standard Life Aberdeen Plc 460,899 460,899 0.00 9,985 10,204 2.19
2018-05-09 13F-HR IFP Advisors, Inc 664 677 1.96 14 15 7.14
2016-11-14 13F-HR EDMOND DE ROTHSCHILD (SUISSE) S.A. 20,000 5,000 -75.00 289 82 -71.63
2018-05-15 13F-HR CSS LLC/IL 24,103 25,303 4.98 522 560 7.28
2018-05-15 13F-HR Gramercy Funds Management LLC 186,086 0 -100.00 4,029 0 -100.00
2018-05-15 13F-HR EDMOND DE ROTHSCHILD HOLDING S.A. 5,000 5,000 0.00 108 111 2.78
2018-05-03 13F-HR BRONFMAN E.L. ROTHSCHILD, L.P. 706 706 0.00 15 16 6.67
2018-05-14 13F-HR RAYMOND JAMES & ASSOCIATES 46,351 46,324 -0.06 1,004 1,026 2.19
2018-05-08 13F-HR DOLIVER CAPITAL ADVISORS, INC. 19,550 13,922 -28.79 423 308 -27.19
2018-05-07 13F-HR Shaker Financial Services, LLC 26,811 42,811 59.68 580 948 63.45
2018-05-10 13F-HR BRINKER CAPITAL INC 11,376 252
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 1,045,446 1,087,315 4.00 22,634 24,073 6.36
2018-05-11 13F-HR IAT REINSURANCE CO LTD. 68,399 68,399 0.00 1,481 1,514 2.23
2018-05-15 13F-HR FIRST WILSHIRE SECURITIES MANAGEMENT INC 70,712 66,885 -5.41 1,531 1,481 -3.27
2018-07-13 13F-HR Deschutes Portfolio Strategy, LLC 194,897 167,592 -14.01 4,315 3,503 -18.82
2017-08-10 13F-HR ABERDEEN ASSET MANAGEMENT PLC/UK 568,834 568,834 0.00 9,443 10,626 12.53
2018-07-20 13F-HR WHITTIER TRUST CO 2,336 0 -100.00 52 0 -100.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 368 368 0.00 8 8 0.00
2018-05-14 13F-HR Bulldog Investors, LLC 700,385 836,651 19.46 15,163 18,523 22.16
2018-05-15 13F-HR WOLVERINE ASSET MANAGEMENT LLC 0 28,665 0 634
2018-05-15 13F-HR Thomas J. Herzfeld Advisors, Inc. 14,537 14,537 0.00 315 322 2.22
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 22,757 22,781 0.11 425 464 9.18
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 3,759 12,915 243.58 81 287 254.32
2018-05-14 13F-HR MORGAN STANLEY 28,919 27,997 -3.19 625 620 -0.80
2017-01-09 SC 13G/A CITY OF LONDON INVESTMENT GROUP PLC 2,476,513 3,441,987 38.99
2018-05-10 13F-HR Stratos Wealth Partners, LTD. 86 86 0.00 2 2 0.00
2018-05-14 13F-HR LAZARD ASSET MANAGEMENT LLC 2,133,471 1,935,671 -9.27 46,189 42,855 -7.22
2018-05-15 13F-HR UBS Group AG 11,023 11,752 6.61 239 260 8.79
2017-02-10 13F-HR BlackRock Advisors LLC 1,000 1,000 0.00 16 15 -6.25
2018-05-15 13F-HR Virtus Investment Advisers, Inc. 11,037 0 -100.00 0 0
2018-05-15 13F-HR BARCLAYS PLC 2,496 2,496 0.00 54 55 1.85
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 109 720 560.55 2 16 700.00
2018-05-14 13F-HR INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 294 7
2018-05-11 13F-HR CITIGROUP INC 207 207 0.00 4 5 25.00
2018-05-11 13F-HR CITY OF LONDON INVESTMENT MANAGEMENT CO LTD 4,190,605 4,335,711 3.46 90,789 96,795 6.62
2018-05-11 13F-HR SEI INVESTMENTS CO 20 0 -100.00 0 0
2018-05-14 13F-HR BOOTHBAY FUND MANAGEMENT, LLC 34,180 757
2018-07-06 13F-HR Versant Capital Management, Inc 180 0 -100.00 3 0 -100.00
2018-05-15 13F-HR 1607 Capital Partners, LLC 439,376 433,776 -1.27 9,512 9,604 0.97
2018-05-15 13F-HR Saba Capital Management, L.P. 66,794 1,479

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

JP Morgan’s top-performing fund manager counts on China’s youngster to defend her title

2018-06-14 scmp
The firm’s China Fund has delivered a 38pc return over the past year, thanks to gains from China’s online entertainment and private school stocks (2-0)

Weekly CEF Roundup: Fee Reductions At TSLF And EGIF

2018-06-09 seekingalpha
The Weekly CEF Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund [CEF] sectors in the last week, as well as to highlight recently concluded or upcoming corporate actions on CEFs, such as tender offers. Most of the information has been sourced from CEFInsight or the Closed-End Fund Center. I will also link to some articles from Seeking Alpha that I have found for useful reading over the past week. (9-1)

Weekly CEF Roundup: May 18, 2018

2018-06-03 seekingalpha
The Weekly CEF Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund [CEF] sectors in the last week, as well as to highlight recently concluded or upcoming corporate actions on CEFs, such as tender offers. Most of the information has been sourced from CEFInsight or the Closed-End Fund Center. I will also link to some articles from Seeking Alpha that I have found for useful reading over the past week. (6-0)

Weekly CEF Roundup: DSE Cuts Distribution By -31%

2018-05-21 seekingalpha
The Weekly CEF Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund (NYSEMKT:CEF) sectors in the last week, as well as to highlight recently concluded or upcoming corporate actions on CEFs, such as tender offers. Most of the information has been sourced from CEFInsight or the Closed-End Fund Center. I will also link to some articles from Seeking Alpha that I have found for useful reading over the past week. (6-0)

Weekly CEF Roundup: City Of London Battles The China Fund

2018-05-11 seekingalpha
The Weekly CEF Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund [CEF] sectors in the last week, as well as to highlight recently concluded or upcoming corporate actions on CEFs, such as tender offers. Most of the information has been sourced from CEFInsight or the Closed-End Fund Center. I will also link to some articles from Seeking Alpha that I have found for useful reading over the past week. (2-0)

CUSIP: 169373107